AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software.
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...
BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and ...
Marks the Completion of NanoACTIV Integration Across the Company’s Entire Additively Manufactured and Wrought Titanium Spinal ...
Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results